Unmatched Speed
Under one-hour eligibility TAT keeps your trials on track and reduces delay to randomization.
Retina Trial Endpoints. AI-Powered. Expert-Validated.
OIRRC delivers precision retinal imaging endpoints with industry-leading speed, accuracy, and transparency — so you can move trials forward with confidence.
Under one-hour eligibility TAT keeps your trials on track and reduces delay to randomization.
Expert graders, dual read, and adjudication deliver high-quality, regulator-ready endpoints.
Flexible ingestion and standardized protocols across all major imaging platforms.
Real-time access to trial imaging status and reporting keeps sponsors aligned at every step.
Deep retinal imaging excellence across indications, endpoints, and trial phases.
Purpose-built technology for ophthalmic trials: AI-supported review, human-verified oversight, multimodal structure-function analysis, reproducible atrophy measurement, and sponsor-visible operational tracking.
AI-supported upload, image QC, pre-grade assistance, and expert adjudication workflows designed to help trial teams identify imaging issues earlier and move screening decisions faster.
Learn moreImage-guided microperimetry and multimodal structure-function analysis for retinal trials, connecting functional testing with retinal imaging to support richer endpoint interpretation.
Learn moreStandardized FAF and DDAF quantification for geographic atrophy and inherited retinal disease programs, supporting reproducible lesion measurement and longitudinal change analysis.
Learn moreSponsor-facing reading-center platform visibility for grading queues, QC status, turnaround time metrics, adjudication, operational oversight, and audit-ready traceability.
Learn moreA concise preview of OIRRC-led scientific sessions.
Presenter: Quan Nguyen, MD, MSc
Presenter: Diana Do, MD
Presenter: Yasir Sepah, MBBS
CTS Retina 2026 · Las Vegas, NV
Meet OIRRC in Las Vegas for a focused conversation on faster, expert-validated retina trial imaging.
Case Study
See how a global biotech sponsor reduced eligibility determination timelines while maintaining exceptional endpoint quality.
Complete the form below and our team will share the CTS case study and follow up with the most relevant next step.